49th week of 2008 patent applcation highlights part 50 |
Patent application number | Title | Published |
20080300114 | ELLIPTICAL EXERCISE MACHINE WITH ADJUSTABLE RAMP - An elliptical exercise machine with adjustable ramp is provided and comprises a frame, first and second reciprocating foot supports, each foot support having a foot placement pad, first and second swing arms being pivotally connected to an upright support structure, first and second link arms being connected to a respective swing arm and a second end of each link arm being interconnected to a second end of a respective reciprocating foot support, a drive assembly positioned on the upright support structure, wherein a first end of each reciprocating foot support is movably linked to the drive assembly, and a ramp assembly adjustably linked to the frame by an adjustment mechanism coupled to the frame and the ramp assembly, the adjustment mechanism being configured to adjust the position of the ramp assembly and to thereby adjust stride movements of the respective foot placement pads. | 2008-12-04 |
20080300115 | REAR MOUNTED PIVOTING TREADMILL CUSHIONING - A treadmill is described herein that utilizes a simple mechanism that absorbs impacts delivered to the treadmill by a user during use. The treadmill includes a frame for supporting an endless belt. A forward structure supports a first end of the frame. A pivoting structure supports and the second end of the frame and provides impact absorption. The pivoting structure includes a pivot arm that is pivotally affixed to an underside of the frame. A roller is mounted on a roller axle proximate the free end of the pivot arm. A spring is provided that has a first end in communication with the frame and has a second end in communication with the pivot arm for biasing the pivot arm away from the frame. Preferably, the spring surrounds a limiter that limits the maximum amount of travel that the pivot arm can extend away from the frame. | 2008-12-04 |
20080300116 | HANDICAPPED ACCESSIBLE EXERCISE MACHINE - A handicapped accessible exercise apparatus having a central housing with two pivoting extension arms. Cables extend from weight stacks within the housing to movable cable guides on the arms for engagement by a user. By adjusting the positions of the arms and the cable guides, the apparatus can be configured to facilitate various exercises and to accommodate users of various sizes. The apparatus is provided with button-operated locks for allowing users with limited manual dexterity to easily lock and unlock the positions of the extension arms and the cable guides. | 2008-12-04 |
20080300117 | RESISTANCE EXERCISE DEVICE - A resistance exercise device comprising at least one handle and a cord having a pair of ends and a length extending between the pair of ends, the handle being secured to one of the ends of the cord, the cord being stretchable to extend the length and comprising a plurality of tubes extending substantially the entire length of the cord, the tubes being conjoined together along substantially the entire length of the cord by means of braiding. The tubes are conjoined together such that the tubes are snug along substantially the entire length of the cord and such that each of the tubes is in contact with at least one of the other tubes substantially along the entire length of the cord. The resistance exercise device may further comprise a plug and sleeve for securing the handle to the end of the cord. | 2008-12-04 |
20080300118 | Lateral training system and method - An exercise apparatus and method for applying one or more lateral resistive loads to participants performing complex motions at low or high speeds to condition one's body to better and more quickly perform physical movements at high speeds. Elastic members may be used to generate resistance emanating from a ground-based or vertically-positioned apparatus. The elastic members may connect to one or more of the following body parts simultaneously: feet, thighs, waist, hands, elbows or shoulders. The apparatus may be mechanically designed to fully retract the elastic members into the apparatus to maintain resistance while participants are in close proximity to the apparatus. The apparatus may provide a plurality of self-contained elastic members and provides participants with the ability to alter the vertical and horizontal positions of each elastic member's emanation point from the apparatus. This provides the ability to control applied resistance vectors between the attachment point on the participant and the apparatus. | 2008-12-04 |
20080300119 | OSCILLATION-TYPE EXERCISE DEVICE - An oscillation-type exercise device is provided with a pair of reins on the right and on the left disposed in front of the user seated on a seat portion. The base ends of a pair of the reins are coupled to a pair of extensible mechanisms housed inside the seat portion. Handle portions formed almost in the shape of a ring so as to be gripped by the user are attached to the tip ends of a pair of the reins. Each extensible mechanism drives a rotary plate to rotate by the driving of a motor, and changes the length of the rein, that is, it causes the rein to substantially extend and retract. Accordingly, it is possible to exert an exercise effect not only on the lower back and the legs but also to the upper half of the body. | 2008-12-04 |
20080300120 | CREASING DEVICE FOR CORRUGATED BOARD SHEET AND CORRUGATED-BOX MAKING MACHINE - A slotter-creaser unit includes an upper creasing head and a lower creasing head. A protruding portion is arranged on a periphery of the lower creasing head in a circumferential direction. A first pressing portion and a second pressing portion having different lengths and different curvature radiuses in a width direction are arranged opposite to each other across the protruding portion and in an alternate manner in the circumferential direction. | 2008-12-04 |
20080300121 | Method and apparatus for making skirtless seals - A machine and method for making bags is described and includes a web traveling from an input section to a rotary drum, to an output section. The rotary drum includes at least one seal bar, having a single sealing zone, and a weakening zone disposed within the single sealing zone. The single sealing zone may be a heated perforator, includes a heating wire. The heating wire may be an NiCr wire stitched into the heater, and be disposed on a cap or on the seal bar. The weakening zone may create a line of weakness that is uniform or varies in intensity. The sealing zone may include temperature zones, cartridge heaters, cooling air, or heated air, or a source of ultrasonic, microwave or radiative energy. | 2008-12-04 |
20080300122 | Method And Apparatus For Making Bags - A method and apparatus for making bags is disclosed. It includes receiving a film and imparting a plurality of successive seals to the film to form bags. The location of the imparted seals is determined by monitoring at least two sensors. A plurality of perforations are imparted to the film at locations relative to a corresponding seal in response to the determination. The position of a perforator such as rotary position, of a knife may be controlled in response to determining the location. The seals may be formed by a rotary drum, and the perforation by a rotary knife. The sensors may be at the same or different cross machine direction and/or machine direction locations. Startup may include adjusting and recording the position of a prior perforation relative to a prior corresponding seal, and using that recording as a base relative location in another embodiment. | 2008-12-04 |
20080300123 | Article Handling Device - A device for fully erecting a flat collapsed carton into an erected carton sleeve, the device comprising an arm linkage comprising a first arm ( | 2008-12-04 |
20080300124 | CENTRIFUGE - According to an aspect of the present invention, there is provided a centrifuge in which a steam sterilization of a sample flow passage is performed, the centrifuge including: a rotor configured to centrifuging a liquid sample; a drive portion that drives and rotates the rotor; a chamber that accommodates the rotor therein, the chamber having a first and a second penetration holes provided on an upper and a bottom portions thereof, respectively; and a first and a second valves disposed on the first and the second penetration holes, respectively; wherein a cooling gas is introduced through one of the first and the second penetration holes and discharged through the other to cool a periphery of the rotor before or after execution of a centrifuging operation of the liquid sample. | 2008-12-04 |
20080300125 | OPTICAL GLASSES OF THE DENSE BARIUM FLINT POSITION - The present invention refers to optical glasses designated to be used in the areas of imaging, sensors, microscopy, medical technology, digital projection, photolithography, laser technology, wafer/chip technology as well as telecommunications, optical communications engineering and optics/illumination in the automotive sector with a refractive index nd of 1.60≦nd≦1.72 and/or an Abbe number vd of 32≦vd≦45 with pronounced short flint character, good chemical resistance, excellent resistance to crystallization, good solarization stability and the following composition (in % by weight based on oxides): | 2008-12-04 |
20080300126 | LOW-MELTING LEAD-FREE SOLDER GLASS AND USES THEREOF - The low melting solder glass contains, in wt. % on an oxide basis, >1-2, SiO | 2008-12-04 |
20080300127 | Aluminum titanate ceramic forming batch mixtures and green bodies with pore former - A ceramic forming batch mixture including inorganic batch materials, such as sources of alumina, titania, and silica, a low amount of one or more pore formers including at least one starch; an organic binder; and a solvent. Also disclosed is a method for producing a ceramic article involving mixing the inorganic batch materials with the low amount of pore former, adding an organic binder and a solvent, forming a green body; and firing the green body. A green body having a low amount of the one or more pore formers including starch is disclosed. | 2008-12-04 |
20080300128 | Process for Producing an Aluminum Nitride Sintered Body - An aluminum nitride sintered body having resistance to plasma gas and high thermal conduction and having excellent optical properties. The aluminum nitride sintered body of the present invention is characterized in that the proportion of positrons which are annihilated within a period of 180 ps (picoseconds) in the aluminum nitride crystal, as determined in the defect analysis using a positron annihilation method, is not less than 90%, and the sintered body preferably has a thermal conductivity of not less than 200 W/mK. | 2008-12-04 |
20080300129 | CERAMIC MATERIAL, COMPOSITIONS AND METHODS FOR MANUFACTURE THEREOF - The present invention relates to a method of producing a ceramic material comprising the steps of: a) mixing a first clay composition comprising silica and a silicate mineral with a second clay composition; and b) firing the mixed clay composition from step a) to form a ceramic product. The present invention also relates to an engobe clay composition, sanitary ware and methods of productions thereof. | 2008-12-04 |
20080300130 | Catalyst For Improving The Adiabatic Steam Reforming Of Natural Gas - A catalyst for adiabatically prereforming a feedstock wherein the catalyst comprises 1 to 20 wt. % nickel and 0.4 to 5 wt. % potassium on a calcium aluminate support. The overall catalyst porosity is greater than 40% with greater than 70% of the overall catalyst porosity contributed by pores having pore diameters of at least 500 Å, and having a median pore diameter greater than 2600 Å, and having a nitrogen BET area less than 6.5 m | 2008-12-04 |
20080300131 | CATALYTIC ADSORBENTS OBTAINED FROM MUNICIPAL SLUDGES, INDUSTRIAL SLUDGES, COMPOST AND TOBACCO WASTE AND A ROTARY DRYING PROCESS FOR THEIR PRODUCTION - A method for producing an adsorbent, having the steps of combining a first sludge and a second material to form a mixture, thermally drying the mixture, and pyrolizing the mixture using at least four temperature zones wherein each temperature zone is set between about 600° C. and 1,100° C. The first sludge is a municipal sludge or an industrial sludge, and the second material is a compost material or one of municipal sludge or industrial sludge differing from the first sludge. The compost material is at least one of tobacco waste, waste paper and wood char, or a combination thereof. Further, the drying can happen in two stages. Each stage can include two separate temperatures. | 2008-12-04 |
20080300132 | MERCURY REMOVAL SORBENT - A sorbent composition comprising a vanadium compound and a ZrO | 2008-12-04 |
20080300133 | Oxygen Scavenger/Indicator - The invention relates to an oxygen scavenger/indicator which contains at least one oxygen sorbent comprising a metal or a metal compound which can be transferred by oxygen into a higher oxidation level. Furthermore, a complexing agent or redox indicator for the sorbent and also an electrolyte are contained in addition. The indicator effect is effected by a change in the physical properties of the oxygen sorbent which is initiated by complex formation and/or interaction with the redox indicator. | 2008-12-04 |
20080300134 | Derivatives of Avermectin, Avermectin Monosaccharide and Avermectin Aglycone - A compound of the formula (I) wherein the bond between carbon atoms 22 and 23 indicated with a broken line is a single or double bond, n is 0, 1 or 2, R | 2008-12-04 |
20080300135 | 5-Alkyl-7-Amino-6-Heteroaryl-1,2,4-Triazolo[1,5-A]Pyrimidine Compounds and Their Use for Controlling Harmful Fungi - The present invention relates to 7-amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds of the formula (I), | 2008-12-04 |
20080300136 | Insecticidal 2-Acylaminothiazole-4-Carboxamides - 2-Acylaminothiazole-4-carboxamides of the formula (I) and application thereof as an insecticide. | 2008-12-04 |
20080300137 | Polypeptide Extracted from Plants of the Genus Lupinus or Produced in Recombinant Form, Nucleotide Sequence Encoding It and Its Use in animal Nutrition, as a Plant Growth Promoter and in the Fight Against Pathogenic Fungi - This invention is related to the extraction of a protein from the seeds, cotyledons or plantlets of | 2008-12-04 |
20080300138 | Dioxazinyl-Substituted Thienylsulphonylaminocarbonyl Compounds - The invention relates to novel substituted thienylsulfonylaminocarbonyl compounds of the formula (I), | 2008-12-04 |
20080300139 | Method for Controlling Aquatic Weeds - The invention relates to a method for controlling aquatic weeds by applying a herbicidally effective amount of at least one inhibitor of p-hydroxyphenylpyruvate dioxygenase (HPPD) or an agriculturally acceptable salt, ester or amide thereof to aquatic weeds and/or their aqueous habitat containing seeds or other propagating organs of said aquatic weeds. | 2008-12-04 |
20080300140 | Methods for Antibody Library Screening - The present invention provides a method of screening a library of molecules to identify and/or select one or more members thereof which are candidate binding partners for one or more ligands comprising: a) contacting an expression library in solution with one or more ligands; b) capturing ligands which have become bound to one or more members of the expression library onto a solid phase; and c) detecting the presence of a ligand, thereby detecting the presence of one or more members of the expression library which are candidate binding partners for the ligand. | 2008-12-04 |
20080300141 | Neoepitope Detection of Disease Using Protein Arrays - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 8. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim | 2008-12-04 |
20080300142 | Methods, Reagents and Kits for Detection of Nucleic Acid Molecules - Methods, reagents and kits are provided for the production and use in detection assays of labeled nucleic acid molecules wherein a labeling molecule is attached directly to the 3′ end of the nucleic acid molecules. | 2008-12-04 |
20080300143 | ENDOGENOUS ANTISENSE RNA EXPRESSION ANALYSIS SYSTEM - Provided is a novel endogenous antisense RNA expression analysis system capable of comprehensively and highly-precisely detecting endogenous antisense RNA including noncoding antisense RNA. A probe set containing one or more probes designed for an antisense strand sequence (Artificial Antisense Sequence: AFAS) under the conditions optimal for hybridization, by artificially defining an antisense strand of known cDNA; a microarray containing the AFAS probe set; detection method of endogenous antisense RNA wherein the microarray and RNA labeling by random priming are combined, and the like. | 2008-12-04 |
20080300144 | Sensor for Biomolecules and a Method for Preparing and Using the Same - Disclosed is a method of preparing a sensor for the analysis of a sample fluid, said sample fluid containing one or more target molecules. The method comprises the steps of applying a non-activated porous organic polymer membrane with probes in the form of an array of probe locations, said probes being able to specifically bind to said one or more target molecules. Furthermore, the method comprises the steps of blocking areas remaining free of probes of said porous organic polymer membrane with one or more blocking substances and forcing the sample fluid repeatedly in one or two directions through the pores of said porous organic polymer membrane. Also disclosed is a sensor for the analysis of a sample fluid. | 2008-12-04 |
20080300145 | In vivo high throughput selection of RNAi probes - In mammalian systems, RNA interference (RNAi)-based suppression of target gene expression may be activated by delivery of RNAi probes such as double stranded small interfering RNA (siRNA) molecules or short hairpin RNAs (shRNAs), where the RNAi probe sequence is homologous to the target-gene. A reliable and quantitative method is provided for the rapid and efficient identification of RNAi probes that are most effective in providing RNAi-mediated suppression of target gene expression. This method may be used for high-throughput screens to identify effective RNAi probes. | 2008-12-04 |
20080300146 | Bio Chip Device with a Sample Compartment and a Light Sensitive Element, Method for the Detection of Fluorescent Particles Within at Least One Sample Compartment of a Bio Chip Device - The invention provides a bio chip device comprising at least one sample compartment and at least one light sensitive element, the at least one sample compartment being provided on a first side of the at least one light sensitive element, wherein incident light is provided incident from a second side opposite of the first side of the at least one light sensitive element. Further, the invention provides a method for the detection of fluorescent particles within at least one sample compartment of a bio chip device. | 2008-12-04 |
20080300147 | Detection and Treatment of Fibrotic Disorders - The present invention provides a method for detecting a fibrotic disorder in a subject by: (a) providing a biological sample obtained from the subject (such as endometrium, peritoneal fluid, and/or smooth muscle cells); (b) analyzing the expression of at least one gene that is differentially expressed in the fibrotic disorder of interest; and (c) correlating the expression of the gene(s) with the presence or absence of the fibrotic disorder in the subject. The present invention also provides a method and compositions for modulating the expression of genes that are differentially expressed in fibrotic tissues, compared to normal tissues. Restoration of gene expression to levels associated with normal tissue is expected to ameliorate at least some of the symptoms of the fibrotic disorder. This method includes the step of contacting the tissue with an agent that modulates expression of one or more differentially expressed genes in the tissue. The present invention also includes arrays, such as microfluidic cards, for detecting differential gene expression in samples of fibrotic tissue. | 2008-12-04 |
20080300148 | MICROFLUIDIC DEVICE FOR SIMULTANEOUSLY CONDUCTING MULTIPLE ANALYSES - Provided is a rotatable microfluidic device for conducting simultaneously two or more assays. The device includes a platform which can be rotated, a first unit which is disposed at one portion of the platform and detects a target material from a sample using surface on which a capture probe selectively binds to the target material is attached, and a second unit which is disposed at another portion of the platform and detects a target material included in the sample by a different reaction from the reaction conducted in the first unit. | 2008-12-04 |
20080300149 | Polysaccharide based cement additives - A composition comprising a carboxylated, sulfonated polysaccharide and a wellbore servicing fluid. A wellbore servicing composition comprising a hydraulic cement and a carboxylated, sulfonated polysaccharide. A wellbore servicing composition comprising a polysaccharide having carboxylate and sulfonate groups. | 2008-12-04 |
20080300150 | Methods of using polysaccharide based cement additives - A method of servicing a wellbore comprising introducing to the wellbore a wellbore servicing fluid comprising an additive composition comprising a polysaccharide having carboxylate and sulfonate groups. A method of servicing a wellbore comprising preparing at the well site an additive composition comprising a polysaccharide having carboxylate and sulfonate groups,introducing the additive composition into a wellbore servicing fluid, and placing the wellbore servicing fluid into a subterranean formation. A method of preparing a wellbore servicing fluid comprising contacting a polysaccharide composition with an oxidizing agent to form an oxidized polysaccharide, and contacting the oxidized polysaccharide with a sulfonating agent to form a carboxylated sulfonated polysaccharide, and contacting the carboxylated sulfonated polysaccharide with a wellbore servicing fluid. | 2008-12-04 |
20080300151 | Oil-well cement fluid loss additive compostion - The present invention relates to compositions and use of fluidized polymer suspensions containing allyloxy linkage and its functional derivatives, and water soluble polymers for use in oil field applications as fluid additives for drilling and cementing processes. | 2008-12-04 |
20080300152 | Methods and Compositions for Crosslinking Polymers with Boronic Acids - The present invention provides a method of forming a viscosified treatment fluid comprising: providing a treatment fluid that comprises water and a gelling agent; contacting the treatment fluid with a boronic acid crosslinking agent so as to form a crosslinked gelling agent, wherein the boronic acid crosslinking agent comprises a compound having the formula: | 2008-12-04 |
20080300153 | Use of Nano-Sized Clay Minerals in Viscoelastic Surfactant Fluids - Nano-sized clay minerals enhance the viscosity of aqueous fluids that have increased viscosity due to the presence of viscoelastic surfactants (VESs). In one non-limiting theory, the nano-sized clay mineral viscosity enhancers associate, link, connect, or relate the VES micelles thereby increasing the viscosity of the fluid, possibly by mechanisms involving chemisorption or surface charge attractions. The nano-sized clay particles may have irregular surface charges. The higher fluid viscosity is beneficial to crack the formation rock during a fracturing operation, to reduce fluid leakoff, and to carry high loading proppants to maintain the high conductivity of fractures. | 2008-12-04 |
20080300154 | LUBRICATING OIL WITH ENHANCED PROTECTION AGAINST WEAR AND CORROSION - Provided is a lubricating oil composition comprising: (a) a major amount of an oil of lubricating viscosity; and (b) one or more borated alkaline earth metal alkyltoluene sulfonate detergents; wherein the lubricating oil composition comprises no more than about 0.20 wt. % of phosphorus and no more than about 0.50 wt. % of sulfur. | 2008-12-04 |
20080300155 | GEAR OIL HAVING LOW COPPER CORROSION PROPERTIES - A gear oil additive composition and gear oil composition comprising a organic polysulfide having at least 30 wt % of a dialkyl polysulfide compound or mixture of dialkyl polysulfide compounds, a thiadiazole; and at least one ashless phosphorus-containing wear inhibitor compound is disclosed as having low yellow corrosion in axles and transmissions. | 2008-12-04 |
20080300156 | Lubricant For Conveyor Chains For Packaged Products - A lubricant for conveyor chains of bottled products, set for lubricating through direct application without dilution and in a discontinual way, in prolonged intervals, leaving a layer or film on the surface of the conveyor chain. The lubricant is composed of an homogeneous mixture of one or more fluids of silicon such as emulsified polydimethylsiloxane; one or more fatty acids such as the oleic acid; one or more amines such as the tensoactive product derived from an ethoxylated amine; one or more hydrocarbons such as the white mineral oils; one or more emulsifiers such as the sorbitan monooleate; and one or more polyglycols such as the polyalkylene-glycol, and alternatively a microbicide. | 2008-12-04 |
20080300157 | Lubricating oil compositions having improved low temperature properties - A lubricating base oil is disclosed comprising a mixture of gas-to-liquids (GTL) base stock/base oil, hydrodewaxed or hydroisomerized/catalytic (and/or solvent) dewaxed wax derived base stock/base oil and from about 1 to 95% by weight of an alkylated naphthalene or alkylated benzene synthetic oil having a pour point of 0° C. or less. The pour point of the base oil is dramatically lowered by the addition of the synthetic oil. | 2008-12-04 |
20080300158 | LIQUID DETERGENT COMPOSITION - A method of cleaning dishware with a liquid detergent composition having an amphiphilic graft polymer, to provide improved grease cleaning and sudsing. | 2008-12-04 |
20080300159 | Mixed Powder or Mixed Granule Based on Glutamic Acid-N, N-Diacetic Acid and Salts Thereof - A mixed powder or mixed granule comprising at least 80% by weight of a mixture of
| 2008-12-04 |
20080300160 | COMPOSITIONS INCLUDING MAGNESIUM ION, CALCIUM ION, AND SILICATE OR CARBONATE AND METHODS EMPLOYING THEM TO REDUCE CORROSION AND ETCH - The present invention relates to compositions including a water soluble magnesium salt, water soluble calcium salt, and silicate or carbonate, which have a beneficial effect on corrosion during cleaning. The present compositions can reduce corrosion of glass or aluminum. The present invention also relates to methods employing these compositions. | 2008-12-04 |
20080300161 | Ethylenically unsaturated amine salts of sulfonic, phosphoric and carboxylis acids - Disclosed are ethylenically unsaturated amine salts of sulfonic, phosphoric and carboxylic acids. The salts are surface active agents which are useful in a variety of applications as primary and/or secondary surfactants. The salts are especially useful as surfactants in emulsion polymerization reactions. | 2008-12-04 |
20080300162 | Solid Fabric Softening Composition - A solid fabric softening composition which is suitable for adding to a heated tumble dryer along with fabric articles comprises a cationic softening agent, a sublimable carrier substance and talc. The composition disintegrates to provide softening with a reduction in risk of greasy spots. | 2008-12-04 |
20080300163 | Modified Human Four Helical Bundle Polypeptides And Their Uses - Modified human four helical bundle (4HB) polypeptides and uses thereof are provided. | 2008-12-04 |
20080300164 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making - A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described. | 2008-12-04 |
20080300165 | Purposeful Movement Of Human Migratory Cells Away From An Agent Source - This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response. | 2008-12-04 |
20080300166 | Treatment of Melanoma with Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 2008-12-04 |
20080300167 | Patched genes and uses related thereto - Methods for isolating patched genes, including the mouse and human patched genes, as well as invertebrate patched genes and sequences, are provided. Decreased expression of patched is associated with the occurrence of human cancers, particularly basal cell carcinomas of the skin. The patched and hedgehog genes are useful in creating transgenic animal models for these human cancers. The patched nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like. The DNA is further used as a diagnostic for a genetic predisposition to cancer, and to identify specific cancers having mutations in this gene. | 2008-12-04 |
20080300168 | INHIBITION OF MIGRATION AND INDUCTION OF CELL DEATH BY THE TYPE II COLLAGEN AMINO PROPEPTIDES - The present invention provides combinations and methods for inducing cell death, inhibiting angiogenesis, and inhibiting cell migration. In particular, the present invention provides methods for inducing cell death in a cell expressing an αvβ3 and/or an αvβ5 integrin. | 2008-12-04 |
20080300169 | Development of Novel Antibiotic Alternatives - The present invention relates to two recombinant colicin expression systems, one utilizing a yeast expression system that produces a protein that is inexpensive to purify, and the other utilizing a plasmid expression system to be used as a probiotic culture. The recombinant colicins provide effective alternatives to conventional antibiotics and may be used to improve the efficiency of pork production, and the safety of its products. | 2008-12-04 |
20080300170 | Compositions and methods for diagnosis and treatment for type 2 diabetes - The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes. | 2008-12-04 |
20080300171 | Use of Dpp-IV Inhibitor to Reduce Hypoglycemic Events - The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof. | 2008-12-04 |
20080300172 | Method and Compositions for the Treatment of Diabetes and Related Complications - The present invention relates to administration of relaxin and related polypeptides to treat a variety of conditions, including diabetes, diabetes-related conditions, Alzheimer's disease, and menopause and related conditions. | 2008-12-04 |
20080300173 | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] - The present invention provides polypeptides that include an O-linked glycoconjugate in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. The polypeptides of the invention include wild-type peptides and mutant peptides that include an O-linked glycosylation site that is not present in the wild-type peptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response. | 2008-12-04 |
20080300174 | COMPOSITIONS AND METHODS FOR ENHANCING FACTOR VIII HEAVY CHAIN SECRETION - FVIII heavy chain mutants are provided which exhibit enhanced secretion from transfected cells and robust anti-coagulation activity. | 2008-12-04 |
20080300175 | Glycopegylated erythropoietin - The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 2008-12-04 |
20080300176 | METHODS OF TREATING NEURODEGENERATIVE DISEASES - The invention relates to the discovery that in an animal model of Parkinson's disease (PD), administration of granulocyte colony-stimulating factor (G-CSF) to rodents having 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD restored the function of dopamine neurons. In these animals, G-CSF treatment increased the number of dopamine neurons in the substantia nigra (SN), G-CSF treatment partially restored the nigrostriatal pathway, and G-CSF restored the function of dopamine to the level before MPTP treatment. The invention also relates to the discovery that treatment of a human patient with corticobasilar ganglionic degeneration, a rare progressive neurological disorder characterized by Parkinsonism and coritcal dysfunction, with G-CSF resulted in a significant improvement in the patient's Unified Parkinson's Disease Rating Scale evaluations as well as measures of activity of daily living. The invention further relates to the discovery that G-CSF treatment of a patient who had suffered an acute stroke resulted in a significant improvement in neurological function, the patient having minimal observable disability seven years later. The methods described herein can be used to treat PD in a mammalian subject (e.g., rodent, human) as well as other neurodegenerative diseases such as Alzheimer's disease, spinal cord injury, and stroke. | 2008-12-04 |
20080300177 | CYCLIC PEPTIDE CXCR4 ANTAGONISTS - Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection. | 2008-12-04 |
20080300178 | Method For Treating Huntington's Disease by Inhibiting Dephosphorylation of Huntingtin at S421 - The present invention relates to a method for treating patients having Huntington's disease by a drug increasing the phosphorylation of huntingtin at position S421, thereby decreasing the polyQ-huntingtin-induced toxicity. | 2008-12-04 |
20080300179 | Bowman-Birk Inhibitor Compositions for Treatment of Muscular Atrophy and Degenerative Muscle Disease - Methods for use of a composition comprising Bowman-Birk Inhibitor (BBI) or a derivative thereof in the treatment and/or prevention of skeletal muscle atrophy, to improve of skeletal muscle function, and to alleviate symptoms and/or slow progression of degenerative skeletal muscle diseases or disorders are provided. | 2008-12-04 |
20080300180 | Growth Hormone Secretagogue Receptor 1A Ligands - The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according to the present invention in the manufacture of a medicament for the treatment of an individual in need thereof. In another aspect, the present invention relates to a method of treatment of an individual in need thereof, comprising administering to said individual one or more of the GHS-R1A ligands disclosed herein, such as e.g. for treatment of cancer cachexia. | 2008-12-04 |
20080300181 | Methods of using IL-1 antagonists to treat neointimal hyperplasia - Methods of using interleukin-1 (IL-1) antagonists to prevent or treat restenosis and other neointimal hyperplasia conditions, including atherosclerosis, vascular access dysfunction, hypertension and related vascular diseases are provided. | 2008-12-04 |
20080300182 | Eye disease treating agent and method for treating eye disease - An eye disease treating agent and a method for treating an eye disease, which use a compound having an interleukin 6 production accelerating activity, are provided. | 2008-12-04 |
20080300183 | Gastrointestinal proliferative factor and uses thereof - The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa. | 2008-12-04 |
20080300184 | TRANSGENIC TIEG NON-HUMAN ANIMALS - Materials and Methods related to a transgenic non-human animal (e.g., a transgenic non-human mammal) whose genome comprises a disrupted TIEG allele are provided. Methods for making such transgenic non-human animals, and using them to identify and characterize agents that affect conditions related to TIEG activity, such as cardiac hypertrophy and bone formation also are provided. In addition, materials and methods related to the treatment of hypertrophic cardiomyopathy are provided. | 2008-12-04 |
20080300185 | Use of IL-1 antagonists to treat gout and pseudogout - Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout or pseudogout in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein gout or pseudogout are inhibited or ameliorated. Preferably, the IL-1 antagonist is the protein of SEQ ID NO:10 (rilonacept). | 2008-12-04 |
20080300186 | Process to produce fibrillar proteins and method of treatment using fibrillar proteins - A method for changing a globular protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, applying the solution to a molecular sizing column with a pore size of at least 70 kDa and eluting with a solution containing detergent. A method for changing an unfolded protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a urea to the solution to unfold the globular protein, applying the solution to a molecular sizing column and eluting with a solution containing detergent. A method for treating cancer comprising the steps of providing a protein, changing the protein into a fibrillar structure, and administering a therapeutically effective amount of the fibrillar structure protein to a patient in need thereof. A method for producing a vaccine adjuvant or antigen adjuvant comprising the steps of providing a protein, and changing the protein into a fibrillar structure. | 2008-12-04 |
20080300187 | MUTATED HOXB4 PROTEINS WITH IMPROVED STABILITY, AND METHODS OF USE THEREOF - A polypeptide, the amino acid sequence of which comprises a sequence as set forth in SEQ ID NO:2, including at least one mutation within the degron domain of the polypeptide encompassed between positions 1 and 35 of the sequence, wherein said at least one mutation reduces the susceptibility of the polypeptide to ubiquitin-proteasome degradation. | 2008-12-04 |
20080300188 | Immunoglobulin Fusion Proteins - Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules. | 2008-12-04 |
20080300189 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION - Pharmaceutical compositions and methods for using are provided for restoring β-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a β-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle. | 2008-12-04 |
20080300190 | PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME - Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome. | 2008-12-04 |
20080300191 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF - Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses. Also disclosed are methods of reducing or preventing the spread of coronavirus, or picornaviruses, and preventing or reducing the replication of coronavirus, or picornaviruses, with the compounds of the present invention | 2008-12-04 |
20080300192 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus - Auristatin-type peptides are disclosed which are highly cytotoxic, synthetically accessible, and can be conjugated to antibodies and other ligands. | 2008-12-04 |
20080300193 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor - The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides. | 2008-12-04 |
20080300194 | Methods of treating emesis using growth hormone secretagogues - The present invention relates to methods of treating or preventing emesis and improving a subject's ASAS score by administering to the subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. | 2008-12-04 |
20080300195 | METABOLIC IMPRINTING - The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life. | 2008-12-04 |
20080300196 | MONOSACCHARIDE DERIVATIVES - The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory, cancer, cardiovascular and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, cancer, cardiovascular diseases, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided. | 2008-12-04 |
20080300198 | Olive Compositions and Methods for Treating Inflammatory Conditions - A method of treating an inflammatory condition with a hydroxytyrosol-rich composition. Improvement is monitored as a reduction in the levels of a biochemical marker such as homocysteine or C-reactive protein. The composition may be administered in an amount and for a period sufficient to effect a drop in the level of the biochemical marker. | 2008-12-04 |
20080300199 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 2008-12-04 |
20080300200 | Therapeutic Furopyrimidines and Thienopyrimidines - The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents. | 2008-12-04 |
20080300201 | Cell Cycle Arrest and Apoptosis - The HIV-1 accessory gene vpr encodes a conserved 96-amino acid protein that is necessary and sufficient for the HIV-1-induced block of cellular proliferation and induction of apoptosis. Expression of vpr in CD4 | 2008-12-04 |
20080300202 | SUBTRACTIVE TRANSGENICS - Described herein are methods for predictable, highly selective expression of a transgene in a human or non-human animal. The methods comprise subtractive transgenics, wherein the expression pattern of one selective promoter is subtracted from the expression pattern of a second selective promoter. Provided are non-human transgenic animals exhibiting a highly selective expression pattern and methods of producing such animals. Further provided are methods of selective expression of a transgene in an animal, including a human, by administration of viral vectors. | 2008-12-04 |
20080300203 | Stable Quantitation and Detection of Immune Response Levels with Non-Zero Background Peptides - The invention relates to a kit comprising MHC Class I and Class II HLA-coated beads containing specific antigenic peptides for binding to antigen-specific T cells and the appropriate negative control peptides. Also provided are methods for making the coated beads and methods for use. The application of these beads go to the stimulation of peripheral blood cell populations and in vitro-stimulated culture for the elicitation of functional activities such as cell activation and signaling, cytokine secretion, proliferation and cytotoxicity activity. | 2008-12-04 |
20080300204 | Alpha-Synuclein Antibodies and Methods Related Thereto - Disclosed are antibodies specific for alpha-synuclein conformers and methods related thereto. For example, disclosed are methods of diagnosing a neurodegenerative monitoring a neurodegenerative disease treatment using the disclosed antibodies. Assays, kits, and solid supports related to alpha-synuclein and antibodies specific for alpha-synuclein are also disclosed. | 2008-12-04 |
20080300205 | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss - The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation. | 2008-12-04 |
20080300206 | Alpha-Synuclein Kinase - The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase. | 2008-12-04 |
20080300207 | PROTEIN PRODUCTION - The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport. | 2008-12-04 |
20080300208 | Isociatrate dehydrogenase and uses therof - The present invention discloses uses for the IDH gene and/or polypeptide and/or modulators thereof in the diagnosis and treatment of apoptosis-related diseases. | 2008-12-04 |
20080300209 | GENE EXPRESSION AND PAIN - The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient. | 2008-12-04 |
20080300210 | Method of Controlling Insects and Virus Transmission - The present invention provides methods and compositions for controlling insects and virus transmission, including a genetic construct for inhibiting virus transmission by an arthropod, a transgenic plant, plant cell or plant tissue, a method of preventing transmission of an arthropod-dependent viral plant disease, a method of delivering an active toxic fragment of a | 2008-12-04 |
20080300211 | MICRORNA INHIBITION FOR THE TREATMENT OF INFLAMMATION AND MYELOPROLIFERATIVE DISORDERS - The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing and treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1α, Sla, Cepbβ, and Bach1, and the like. | 2008-12-04 |
20080300212 | TREATMENT AND PREVENTION OF HYPERPROLIFERATIVE CONDITIONS IN HUMANS AND ANTISENSE OLIGONUCLEOTIDE INHIBITION OF HUMAN REPLICATION-INITIATION PROTEINS - Antisense oligonucleotides that inhibit expression of human replication- initiation protein as well as methods of preventing or treating hyperproliferative conditions using said oligonucleotides are disclosed. One aspect provides an antisense oligonucleotide that inhibits the expression of human replication-initiation protein and has a sequence complementary to at least a portion of a target sequence encoding a human replication-initiation gene. By administering a therapeutically effective amount of an antisense oligonucleotide or by contacting the hyperproliferating cells with an effective amount of one or more antisense oligonucleotides, expression of replication-initiation protein is inhibited. Methods of screening and testing active antisense oligonucleotides for their ability to inhibit gene expression are also disclosed. | 2008-12-04 |
20080300213 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment - The present invention provides the use of an A | 2008-12-04 |
20080300214 | Compounds for the Treatment of Marihuana Dependence, Withdrawal, and Usage - The invention provides methods for treating or suppressing marihuana usage, withdrawal, or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, uridine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal. | 2008-12-04 |